Dexcom Inc DXCM Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$79.41 down $5.05, 5.98% at close Nov 6
Last close · Previous close $84.46
- Market cap
- At the Nov 6 close
- P/E ratio
- 31.26On last 12 months’ EPS
- Diluted EPS
- $2.54Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$79.41down $5.05, 5.98%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$84.46Nov 5
- Volume3.94MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume4.97MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $54.20 to $92.59; now $79.41
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
DXCM beat the S&P 500 in 4 of 7 periods.
| Period | DXCM and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | DXCM: down 4.8% S&P 500: down 5.6% | DXCM beat the S&P 500 by 0.8 percentage points Beat |
| 3M | DXCM: down 4.3% S&P 500: down 4.1% | DXCM trailed the S&P 500 by 0.2 percentage points Trailed |
| YTD | DXCM: up 19.6% S&P 500: up 8.7% | DXCM beat the S&P 500 by 10.9 percentage points Beat |
| 1Y | DXCM: up 36.9% S&P 500: up 10.9% | DXCM beat the S&P 500 by 26.0 percentage points Beat |
| Long term | ||
| 3Y | DXCM: down 16.3% S&P 500: up 75.0% −5.7% vs +20.5% a year | DXCM trailed the S&P 500 by 91.3 percentage points Trailed |
| 5Y | DXCM: down 50.0% S&P 500: up 67.8% −12.9% vs +10.9% a year | DXCM trailed the S&P 500 by 117.8 percentage points Trailed |
| 10Y | DXCM: up 413.2% S&P 500: up 313.1% +17.8% vs +15.2% a year | DXCM beat the S&P 500 by 100.1 percentage points Beat |
$10,000 invested in DXCM 10 years ago (Nov 4, 2016) would be worth about $51,315 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
DXCM beat the S&P 500 in 4 of 7 periods.
| Period | DXCM and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | DXCM: down 4.8% S&P 500: down 5.6% | DXCM beat the S&P 500 by 0.8 percentage points Beat |
| 3M | DXCM: down 4.3% S&P 500: down 4.3% | DXCM matched the S&P 500 Even |
| YTD | DXCM: up 19.6% S&P 500: up 7.8% | DXCM beat the S&P 500 by 11.8 percentage points Beat |
| 1Y | DXCM: up 36.9% S&P 500: up 9.7% | DXCM beat the S&P 500 by 27.2 percentage points Beat |
| Long term | ||
| 3Y | DXCM: down 16.3% S&P 500: up 68.8% −5.7% vs +19.1% a year | DXCM trailed the S&P 500 by 85.1 percentage points Trailed |
| 5Y | DXCM: down 50.0% S&P 500: up 56.9% −12.9% vs +9.4% a year | DXCM trailed the S&P 500 by 106.9 percentage points Trailed |
| 10Y | DXCM: up 413.2% S&P 500: up 252.6% +17.8% vs +13.4% a year | DXCM beat the S&P 500 by 160.6 percentage points Beat |
$10,000 invested in DXCM 10 years ago (Nov 4, 2016) would be worth about $51,315 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$162.82
Closing high on . Now 51.2% below that record.
Split-adjusted daily closes since Apr 14, 2005.
Stock splits
1
4-for-1 on . One share bought before the first split is 4 shares today.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $5.10Bup 13.0%
- Net income
- $991.00Mup 37.5%
- Diluted EPS
- $2.54up 41.1%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $1.11B | $151.70M | $0.38 |
| Q1 FY25 (Mar 31, 2025) | $1.04B | $105.40M | $0.27 |
| Q2 FY25 (Jun 30, 2025) | $1.16B | $179.80M | $0.45 |
| Q3 FY25 (Sep 30, 2025) | $1.21B | $283.80M | $0.70 |
| Q4 FY25 (Dec 31, 2025) | $1.26B | $267.30M | $0.67 |
| Q1 FY26 (Mar 31, 2026) | $1.19B | $199.50M | $0.51 |
| Q2 FY26 (Jun 30, 2026) | $1.31B | $249.10M | $0.64 |
| Q3 FY26 (Sep 30, 2026) | $1.34B | $275.10M | $0.72 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $2.45B | $216.90M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $2.91B | $341.20M | $0.82 |
| FY23 (Dec 31, 2023) | $3.62B | $541.50M | $1.30 |
| FY24 (Dec 31, 2024) | $4.03B | $576.20M | $1.42 |
| FY25 (Dec 31, 2025) | $4.66B | $836.30M | $2.09 |
Margins
- Gross 63.4%
- Operating 24.0%
- Net 19.4%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $1.10BLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$1.41BLast 12 months
- Capital spending$316.10MLast 12 months
- 21.5%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $1.29BLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$1.29BLast 12 months
118% of free cash flow
Balance sheet
- $1.82BAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$1.34BAs of Sep 30, 2026
- Net cash$476.00MAs of Sep 30, 2026
- 1.74As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.53As of Sep 30, 2026
Total debt divided by shareholders’ equity on the Sep 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 7 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✓Current ratio improved: passed
- ✓Share count didn’t rise: passed
- ✓Gross margin improved: passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- 36.5%Last 12 months
Over the last 12 months, Dexcom’s net income was 36.5% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 15.4%Last 12 months
Over the last 12 months, Dexcom’s net income was 15.4% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
About Dexcom Inc
Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Category: IR
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
DXCM news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
DXCM stock FAQ
What is DXCM stock’s price today?
Dexcom (DXCM) traded at $79.41 at the close on , down $5.05 (5.98%) from the previous close of $84.46. Over the past 52 weeks it has traded between $54.20 and $92.59.
If you invested $1,000 in DXCM 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in DXCM on would be worth about $5,132 at the close on , a total return of +413.2%. The same $1,000 would be worth $500 if invested five years ago, $1,369 if invested one year ago, and $34,082 if invested 20 years ago. Past performance doesn’t predict future returns.
What is DXCM’s P/E ratio?
DXCM trades at 31.3 times its diluted earnings over the four quarters to ($2.54 per share), at the close. (How the P/E ratio works.)
How much revenue does Dexcom make?
Dexcom reported $5.1 billion of revenue over the four quarters to , up 13.0% from the twelve months before. In its latest quarter (Q3 FY26, ended ) revenue was $1.3 billion, up 11.2% from a year earlier.
Is Dexcom profitable?
Yes. Dexcom earned $991.0 million of net income over the four quarters to , a net margin of 19.4%, and its operating margin was 24.0% (what margins tell you).
What are DXCM’s earnings per share?
DXCM’s diluted earnings per share were $2.54 over the four quarters to , compared with $1.80 in the twelve months before. The latest quarter (Q3 FY26) brought $0.72 per share, against $0.70 a year earlier (how EPS works).
Does DXCM pay a dividend?
Dexcom hasn’t paid a dividend in the last twelve months.
What is DXCM’s 52-week high and low?
Over the past 52 weeks DXCM has traded as low as $54.20 and as high as $92.59. At $79.41 at the close on , it is 14.2% below that high and 46.5% above the low.
What is DXCM’s all-time high?
DXCM’s highest closing price was $162.82 on , adjusted for stock splits. At $79.41 at the close on , it is 51.2% below that record.
Has DXCM stock ever split?
Yes, once: 4-for-1 on . One share bought before the first split would be 4 shares today.
How has DXCM stock performed?
Including dividends and measured to the close on , DXCM has returned +19.6% so far this year and +36.9% over the past year, and −50.0% over five years (−12.9% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Dexcom in?
Dexcom is in the Healthcare sector and the Medical Devices industry, and is headquartered in California, USA.
What exchange does DXCM trade on?
Dexcom trades on the Nasdaq under the ticker symbol DXCM. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.